Androgen Receptor Current Events | Androgen Receptor News | 2
|
| Page
2 of
28 |
547 Results |
|
|
|
Sort By:
Page Views | Date |
More than 6 months of hormone therapy doesn't help prostate cancer patients live longer
Prostate cancer patients treated with either radiation or surgery who use hormone therapy for longer than six months do not survive any longer than patients who use the treatment for a shorter amount of time. view more (2006-11-06)
Sex hormone signature indicates gender rather than just chromosomes
Help with assigning gender could one day be at hand for intersex individuals whose genital phenotypes and sex chromosomes don't match, thanks to the discovery of a stable sex hormone signature in our cells. view more (2007-10-18)
No link found between low androgen levels and low sexual function in women
No single androgen (sex hormone) level was found to be predictive of low sexual function in women, according to a study in the July 6 issue of JAMA. view more (2005-07-06)
Drug shows activity in men with advanced prostate cancer
A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels - a marker for tumor growth - in men with advanced prostate cancer for whom traditional treatment options have failed. view more (2009-04-09)
New research may show why some prostate cancer recurs after treatment
Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth. view more (2007-10-12)
Inflammatory reaction drives hormone resistance in cancer, study suggests
In the February 10, 2006 Cell, researchers report new evidence to explain why prostate cancer and other hormone-dependent cancers may become resistant to hormone therapies. view more (2006-02-10)
Castrate resistant prostate cancer: New therapeutic approaches
Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden. view more (2009-03-23)
Hormone that affects finger length key to social behavior
The hormones, called androgens, are important in the development of masculine characteristics such as aggression and strength. view more (2009-11-05)
TARGETED BONE THERAPY COULD IMPROVE SURVIVAL OUTCOME FOR PATIENTS WITH ADVANCED PROSTATE CANCER (pp 326, 336)
Patients responding to chemotherapy for advanced prostate cancer could have increased survival times if specific therapy is targeted at sites of skeletal metastases, concludes research published in this week’s issue of THE LANCET. Prostate cancer tends to spread to the bones, and there is a direct relation between the extent of bone... view more... (2001-01-31)
Denosumab increases bone density, cuts fracture risk in prostate cancer survivors
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. view more (2009-08-11)
Antibodies can halve risk of transplant rejection
Giving interleukin-2 receptor antibodies to patients after a kidney transplant can halve the risk of rejection, concludes a study in this week's BMJ. Researchers in Birmingham reviewed eight trials of interleukin-2 receptor antibodies versus placebo in 1,858 patients receiving standard immunosuppressant drugs after kidney transplants. Treatment... view more... (2003-04-10)
Common osteoporosis treatment may help men with prostate cancer suffering from bone loss
Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis. view more (2006-02-27)
Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. view more (2008-01-02)
Cancer researchers add spice to research against rare neuromuscular disease
Scientists who focus on the molecular signaling that underlies prostate cancer have discovered a compound that shows promise against a debilitating neurodegenerative condition known as Kennedy's disease, which is caused by a mutant gene. view more (2007-03-21)
Surgeons pinch more than an inch from the arm to rebuild a micropenis
A surgical procedure being pioneered by University College London (UCL) urologists is enabling men born with a very small penis to acquire an average-sized, functioning penis which not only allows them to urinate normally, but for many, to enjoy a full sex life for the first time. view more (2004-12-06)
UC Davis researchers identify a cellular pathway that makes prostate cancer fatal
Expanding evidence that tiny strands of RNA - called microRNAs - play big roles in the progress of some cancers, UC Davis researchers have identified one that helps jump start prostate cancer cell growth midway through the disease process, eventually causing it to become fatal. view more (2007-11-28)
Androgen deprivation therapy does not keep localized prostate cancer from spreading, new study says
Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of testosterone actually keeps cancer from spreading beyond the prostate. view more (2006-02-27)
Inhaled asthma drugs more effective than oral therapy
Inhaled glucocorticoid drugs are more effective than the newer anti-leukotriene tablets for adults with mild or moderate asthma, concludes a study in this week’s BMJ. view more (2003-03-19)
How advanced prostate cancer becomes resistant to androgen-deprivation therapy
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. view more (2008-06-02)
Prostate cancer therapy increases risk of fractures and cardiovascular-related death
Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis. view more (2009-04-27)
|
|
| Page
2 of
28 |
547 Results |
|
|
|
Sort By:
Page Views | Date |
|
